



Fort Dodge Animal Health
Division of Wyeth
Huizerstraatweg 117
1411 GM NAARDEN
The Netherlands

July 2009

Fort Dodge Launches PropoClear® – the First Lipid-free Injectable Propofol to Offer 28 day Broached Vial Shelf Life

At a seminar in London on 18 June 2009, attended by veterinary anaesthesia experts from across Europe, Fort Dodge Animal Health launched PropoClear, a short-acting, intravenous general anaesthetic for dogs and cats. The company believes that PropoClear, which is based on novel lipid-free micro-emulsion technology, will deliver significant clinical benefits over conventional lipid-based Propofol emulsions. It will also deliver increased cost effectiveness and convenience to practices.

PropoClear is indicated for use as a short acting general anaesthetic for procedures lasting up to five minutes. It is also indicated for the induction and maintenance of general anaesthesia using incremental doses and for the induction of anaesthesia where maintenance is provided by inhalation. Its unique lipid-free, nano-emulsion formulation and its inclusion of antimicrobial preservatives provide the following key benefits to practices:

- **Extended microbial stability**

PropoClear's formulation requires no lipid content and facilitates the inclusion of effective microbial preservatives to reduce the opportunity for microbial contamination. Fort Dodge says that its extended microbial stability has the potential to reduce the risk of post operative infections

- **Broached vial shelf life of 28 days**

Unlike conventional Propofol emulsions which are susceptible to bacterial contamination and must be used or disposed of quickly, broached PropoClear vials have a shelf life of up to 28 days, which Fort Dodge says, will improve clinic compliance and reduce waste



- **Presentation in multi-dose vials (50 and 100 ml)**

PropoClear, which presents as a virtually clear and colourless liquid, is the first product to be offered in multidose vials in a move to make it more convenient and cost-effective for practices, according to Fort Dodge. It has a shelf life of three years unopened.

Commenting on the launch of PropoClear, Dr Jo Murrell, Department of Clinical Veterinary Science, Division of Companion Animals, the University of Bristol, said: “With currently available lipid-based Propofol formulations unused drug should be discarded immediately once the vial has been opened leading to drug wastage or the potential for bacterial contamination of the remaining solution if this regulation is ignored. The new lipid-free Propofol formulation, which also contains antimicrobial preservatives, overcomes this limitation and will provide significant clinical benefits in terms of the 28 day shelf life once broached.”

Jose Manuel Fernandez, Business Manager for Companion Animals at Fort Dodge EMEA, said: “In developing PropoClear, it was our goal to deliver an anaesthetic product with the same proven efficacy as the existing solution but which offered significant benefits in terms of enhanced safety, cost and convenience.”

“PropoClear contains the same concentration of the established active molecule and follows familiar guide dose protocols to ensure ease of use. We have been encouraged by the positive feedback received during product trials and believe the significant advantages it offers, both clinically and financially, to practices in challenging times, will ensure its rapid adoption by veterinary practices across Europe.”

Fort Dodge is a leading manufacturer and marketer of animal health products for the companion animal, equine, livestock, swine and poultry industries in North America and international markets. Key products include ProMeris®, ProMeris Duo®, Duramune®, Fevaxyn®, Duvaxyn®, Suvaxyn®, Poulvac®, Cydectin® and Equest® and Equest Pramox®.

Note to editors:



The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialisation (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information:

Rebecca George

George PR

Tel: 0044 1449 737281